Apotex Receives Health Canada Approval for Aflivu™, a Biosimilar to Eylea®, Available in Pre-Filled Syringe and Vial Formats

Apotex receives Health Canada approval for Aflivu™, a biosimilar to Eylea®, available in pre-filled syringe and vial formats

Newswire.ca Press Release.

Regeneron Pharmaceuticals Receives FDA Accelerated Approval for ...

Lupin receives FDA approval for Loteprednol Etabonate Ophthalmic Gel, 0.38%

Lupin Limited secures FDA approval for Loteprednol Etabonate Ophthalmic Gel, enhancing treatment options for postoperative ocular inflammation and pain.

Regeneron sues Sandoz over Eylea biosimilar

Save (0) Please login to bookmarkClose Username or Email Address Password Remember Me US biotech company Regeneron Pharmaceuticals has sued Sandoz, claiming it is threatening to infringe the patent for its Eylea biologic, used to treat macular degeneration and diabetic macular oedema. Subscribe to Lawyerly to access this article.Already a subscriber? Username or Email Address Password Remember Me Lost your p…